Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Christopher_J._Burns
|
| gptkbp:collaboratesWith |
gptkb:Global_Antibiotic_Research_and_Development_Partnership
gptkb:Biomedical_Advanced_Research_and_Development_Authority |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
novel beta-lactamase inhibitors
|
| gptkbp:focusesOn |
antiviral drugs
antibacterial drugs |
| gptkbp:foundedYear |
2010
|
| gptkbp:founder |
gptkb:Christopher_J._Burns
gptkb:Daniel_Pevear gptkb:Luigi_Xerri |
| gptkbp:headquartersLocation |
gptkb:Malvern,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Venatorx Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:cefepime-taniborbactam
|
| gptkbp:specializesIn |
antibiotic resistance
|
| gptkbp:website |
https://www.venatorx.com/
|
| gptkbp:bfsParent |
gptkb:Apple_Tree_Partners
|
| gptkbp:bfsLayer |
6
|